Topics: FDA, Cancer, Drug Cost, Hepatitis C, High Cholesterol, Biologics and Biosimilars, Let's Talk About Cost
From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results.
Last year, a record number of new treatments and cures that are transforming care for patients fighting debilitating diseases like cancer, hepatitis C, high cholesterol and more were approved by the U.S. Food and Drug Administration. In the midst of all this incredible progress, spending on medicines grew just 0.6 percent in 2017, according to the new IQVIA Institute for Human Data Science “2017 Medicine Use and Spending in the U.S.” report.
This report is further evidence we don’t have to choose between innovation and affordability.
Here are four things you should know about the “2017 Medicine Use and Spending in the U.S.” report:
Learn more at LetsTalkAboutCost.org.
Holly Campbell Holly Campbell is former deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.
Topics: FDA, Cancer, Drug Cost, Hepatitis C, High Cholesterol, Biologics and Biosimilars, Let's Talk About Cost
Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004